Physician profile
Stephen Winston
NPI 1376524017
$4,974.34
in general payments reported to CMS, 2019-2025
38 companies · $467 in 2025
The $467 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $619 · 2021: $826 · 2022: $1,188 · 2023: $693 · 2024: $503 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,662.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,071.90 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $574.64 | 2021-2023 | Vraylar, Ubrelvy, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $527.77 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $482.22 | 2019-2022 | |
| Lilly USA, LLC | $283.71 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $241.82 | 2021-2025 | Trelegy Ellipta |
| Corium, LLC | $232.97 | 2023-2025 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $213.79 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbott Laboratories | $198.48 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $133.02 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.61 | 2019-2025 | Xifaxan |
| Pfizer INC. | $108.82 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $98.10 | 2019-2024 | Rexulti |
| Allergan, INC. | $92.11 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $91.10 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $55.54 | 2019-2020 | |
| Eisai INC. | $49.27 | 2020 | |
| Corcept Therapeutics | $47.27 | 2021 | |
| Esperion Therapeutics, INC. | $38.10 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $26.97 | 2020-2021 | |
| Neos Therapeutics, LP | $24.61 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.51 | 2019 | |
| Exact Sciences Corporation | $18.92 | 2025 | The Cologuard Plus Collection Kit |
| Amgen INC. | $18.09 | 2022 | |
| Astellas Pharma US INC | $18.01 | 2019 | |
| Hikma Pharmaceuticals USA | $17.81 | 2024 | Ryaltris |
| Ibsa Pharma INC. | $17.80 | 2023 | Tirosint, Licart |
| Mylan Specialty L.P. | $16.38 | 2020 | |
| Acadia Pharmaceuticals INC | $16.07 | 2025 | Daybue |
| Sonex Health, INC. | $15.47 | 2025 | Sx-One Microknife |
| Almatica Pharma LLC | $15.12 | 2022 | |
| Adlon Therapeutics L.P. | $14.66 | 2019 | |
| Shire North American Group INC | $14.41 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.66 | 2020 | |
| Daiichi Sankyo INC. | $11.73 | 2019 | |
| Phathom Pharmaceuticals, INC. | $11.66 | 2025 | Voquezna |
| Supernus Pharmaceuticals, INC. | $11.42 | 2021 | |
| Sanofi-Aventis U.S. LLC | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Winston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.